MarketLens
Sign Up

Has Arvinas Finally Turned the Corner with VEPPANU's FDA Approval

5 months ago
SHARE THIS ON:

Has Arvinas Finally Turned the Corner with VEPPANU's FDA Approval

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

AbbVie's New Parkinson's Pill Could Become a Billion-Dollar Drug, Analyst Says

AbbVie won FDA approval Friday for Juvmo (tavapadon), the first selective D1/D5 agonist for Parkinson's disease, with an analyst projecting billion-dollar potential. The approval adds a differentiated...
Stock News•2 months ago

Can BMY's First CELMoD Approval Support Its Growth Strategy?

Bristol Myers won FDA accelerated approval for Zenbexus, the first CELMoD therapy, after data showed it doubled MRD-negative complete response rates, supporting its growth strategy.
Stock News•2 months ago

Arvinas Q2 Earnings Call Highlights

Arvinas is concentrating resources on early-stage oncology and neurology pipeline after H1 2026 milestones, including FDA approval of VEPPANU, the first PROTAC degrader, and an out-licensing deal with...

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates